Showing 2861-2870 of 5646 results for "".
- In-Clinic Hurdles for AI-Based Diabetic Retinopathy Detectionhttps://modernod.com/news/in-clinic-hurdles-for-ai-based-diabetic-retinopathy-detection/2479810/Researchers found mixed results when they tested an artificial intelligence (AI)‒based system for detecting diabetic retinopathy (DR) in a real-world primary care setting in Midland, Australia, according to a Medscape report. In th
- New Display Design Could Make Lightweight, Compact Smart Glasses a Realityhttps://modernod.com/news/new-display-design-could-make-lightweight-compact-smart-glasses-a-reality/2479811/Researchers have developed a fundamentally new approach to a see-through display for augmented reality, or smart glasses. By projecting images from the glass directly onto the eye, the new design could one day make it possible for a user to see information such as directions or restaurant ratings
- AAO: New Study Confirms Mediterranean Diet Prevents AMD Developmenthttps://modernod.com/news/aao-new-study-confirms-mediterranean-diet-prevents-a-leading-cause-of-blindness/2479827/Evidence is mounting that a poor diet plays an important role in the development of age-related macular degeneration (AMD). A large
- NovaBay Pharmaceuticals Names Jack McGovern Interim CEOhttps://modernod.com/news/novabay-pharmaceuticals-names-jack-mcgovern-interim-ceo/2479833/NovaBay Pharmaceuticals announced that Jack McGovern has been named interim Chief Executive Officer, expanding his responsibilities as Chief Financial Officer to include overseeing daily operations. Mark M. Sieczkarek, the company’s previous CEO, remains NovaBay’s Chairman and will focus on strat
- First FDA-Approved Iris Prosthesis Now Available in the United Stateshttps://modernod.com/news/veo-ophthalmics-launches-customflex-artificialiris-in-the-united-states/2479835/VEO Ophthalmics announced the launch of the ‘Customflex ArtificialIris,’ the first iris prosthesis available in the United States. The surgically implanted device received FDA approval on May 30, 2018 for use in children and adults for the treatment of iris defects resulting from cong
- PeptiDream Announces Drug Discovery and Development Agreement with Santen Pharmaceuticalhttps://modernod.com/news/peptidream-announces-drug-discovery-and-development-agreement-with-santen-pharmaceutical/2479839/PeptiDream Inc., a public Kanagawa, Japan-based biopharmaceutical company, announced that it has entered into a broad-based multi-target discovery and development agreement with Osaka-based Santen Pharmaceuticals. Under the agreement, PeptiDream will use its proprietary Peptide Discovery Platform
- Novartis to File for New Lucentis (Ranibizumab) Indication in Retinopathy of Prematurity (ROP)https://modernod.com/news/novartis-to-file-for-new-lucentis-ranibizumab-indication-in-retinopathy-of-prematurity-rop/2479845/Novartis announced results from a phase 3 study of Lucentis (ranibizumab) versus laser surgery (the current standard of care) in premature infants with retinopathy of prematurity (ROP). Unlike laser surgery, which damages eye tissue and can be associated with significant complications such as hig
- Hoya Launches 4-in-1 Multisert Preloaded Delivery System with Vivinex IOLhttps://modernod.com/news/hoya-launches-4-in-1-multisert-preloaded-delivery-system-with-vivinex-iol/2479847/Hoya Surgical Optics officially launched the new multiSert 4-in-1 preloaded delivery system with Vivinex IOL at the European Society of Cataract and Refractive Surgeons (ESCRS) in Vienna, Austria. “MultiSert is
- Novartis to Cut Over 2000 Jobs in Switzerland, UKhttps://modernod.com/news/novartis-to-cut-over-2000-jobs-in-switzerland-uk/2479850/Novartis announced that it will slash more than 2,000 jobs by 2022, including eliminating 1,700 positions in Switzerland and around 400 roles in the UK, as it looks to increase profitability. The move comes as the company consolidates manufacturing and shifts positions elsewhere as part of plans
- Cigna Now Covering Avedro’s FDA-Approved Cross-Linking Procedurehttps://modernod.com/news/cigna-now-covering-avedros-fda-approved-cross-linking-procedure/2479851/Avedro announced that 50 commercial insurance plans now cover Avedro’s FDA-approved corneal cross-linking procedure, following Cigna’s recent announcement that it is covering the Photrexa drug formulations and the KXL System used in the treatment of progressive keratoconus. Other health plans rec